These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression. Zhang J; Tian H; Li J; Ji S; Chen S; Zhu J; Jiang D; Wang L; Li G; Chen M; Wang W; Lin X; Zhuo C Psychiatry Res; 2020 May; 287():112907. PubMed ID: 32179210 [TBL] [Abstract][Full Text] [Related]
4. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373 [TBL] [Abstract][Full Text] [Related]
5. Role of Electroconvulsive Therapy, Ketamine Infusion, and Deep Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Bipolar Depression: A Case Report. Gao K Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929552 [No Abstract] [Full Text] [Related]
6. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Rybakowski JK; Permoda-Osip A; Bartkowska-Sniatkowska A Int J Psychiatry Clin Pract; 2017 Jun; 21(2):99-103. PubMed ID: 28271731 [TBL] [Abstract][Full Text] [Related]
7. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression. de la Salle S; Phillips JL; Blier P; Knott V Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723 [TBL] [Abstract][Full Text] [Related]
8. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101 [TBL] [Abstract][Full Text] [Related]
10. Global functional connectivity density alterations in patients with bipolar disorder with auditory verbal hallucinations and modest short-term effects of transcranial direct current stimulation augmentation treatment-Baseline and follow-up study. Zhuo C; Ji F; Lin X; Tian H; Wang L; Xu Y; Wang W; Jiang D Brain Behav; 2020 Jun; 10(6):e01637. PubMed ID: 32304288 [TBL] [Abstract][Full Text] [Related]
11. Anhedonia in bipolar depression treated with ketamine. Wilkowska A; Wiglusz MS; Arciszewska-Leszczuk A; Gałuszko-Węgielnik M; Cubała WJ Bipolar Disord; 2024 Jun; 26(4):356-363. PubMed ID: 38311367 [TBL] [Abstract][Full Text] [Related]
12. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782 [TBL] [Abstract][Full Text] [Related]
13. Pre-treatment functional connectivity of the cingulate cortex predicts anti-suicidal effects of serial ketamine infusions. Chen X; Zhang B; Yuan S; Luo X; Wang M; Hu Y; Zhou Y; Ning Y Eur Psychiatry; 2023 Mar; 66(1):e31. PubMed ID: 36999368 [TBL] [Abstract][Full Text] [Related]
14. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study. Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP J Affect Disord; 2018 Jan; 225():709-714. PubMed ID: 28922734 [TBL] [Abstract][Full Text] [Related]
15. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Lan XF; Zhang B; Ning YP J Affect Disord; 2020 Oct; 275():38-43. PubMed ID: 32658821 [TBL] [Abstract][Full Text] [Related]
16. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Lally N; Nugent AC; Luckenbaugh DA; Ameli R; Roiser JP; Zarate CA Transl Psychiatry; 2014 Oct; 4(10):e469. PubMed ID: 25313512 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of 24-week pramipexole augmentation in patients with treatment resistant depression. A retrospective cohort study. Tundo A; Betro' S; Iommi M; de Filippis R Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jan; 112():110425. PubMed ID: 34375683 [TBL] [Abstract][Full Text] [Related]
18. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression. Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430 [TBL] [Abstract][Full Text] [Related]
19. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Zheng W; Zhou YL; Liu WJ; Wang CY; Zhan YN; Li HQ; Chen LJ; Li MD; Ning YP J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319 [TBL] [Abstract][Full Text] [Related]
20. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]